Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection, and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy.

Regulus is also advancing several programs toward clinical development in renal, hepatic and central nervous systems diseases, both independently and with our strategic alliance partners.

Type
Public
HQ
San Diego, US
Founded
2007
Size (employees)
65 (est)-29%
Regulus Therapeutics was founded in 2007 and is headquartered in San Diego, US
Report incorrect company information

Regulus Therapeutics Office Locations

Regulus Therapeutics has an office in San Diego
San Diego, US (HQ)
10614 Science Center Dr
Show all (1)
Report incorrect company information

Regulus Therapeutics Financials and Metrics

Regulus Therapeutics Financials

Regulus Therapeutics's revenue was reported to be $72 k in FY, 2017
USD

Revenue (Q1, 2018)

18 k

Net income (Q1, 2018)

(16 m)

EBIT (Q1, 2018)

(15.6 m)

Market capitalization (15-May-2018)

74.9 m

Closing share price (15-May-2018)

0.7

Cash (31-Mar-2018)

10.1 m
Regulus Therapeutics's current market capitalization is $74.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

19.6 m7.7 m20.8 m1.2 m72 k

Revenue growth, %

(61%)171%(94%)

General and administrative expense

17 m

R&D expense

53.2 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

3.8 m1.9 m489 k483 k204 k18 k18 k18 k

General and administrative expense

5.8 m4.2 m5.1 m3.7 m4.8 m4 m7.1 m3.8 m

R&D expense

19.2 m11 m16.8 m18 m14.6 m15.8 m14.3 m11.8 m

Operating expense total

25 m15.2 m21.9 m21.7 m19.4 m19.7 m21.3 m15.6 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

17.8 m37.3 m16 m14.9 m13.5 m

Current Assets

117.2 m165 m134.3 m87.5 m66.7 m

PP&E

3.8 m3.6 m5.4 m11.8 m9.7 m

Total Assets

123.1 m171.5 m141.1 m100.7 m77.8 m
Quarterly
USDQ1, 2018

Cash

10.1 m

Current Assets

51.4 m

PP&E

9.3 m

Total Assets

62.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(18.7 m)(56.7 m)(55.7 m)(81.8 m)(71.9 m)

Depreciation and Amortization

1.4 m1.5 m1.6 m2.3 m2.5 m

Accounts Payable

860 k940 k529 k3.1 m(65 k)

Cash From Operating Activities

(28.3 m)(39.5 m)(49.9 m)(56.9 m)(58.8 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(21 m)(13 m)(21.2 m)(21.1 m)(19.5 m)(20 m)

Accounts Payable

1.1 m2.7 m3 m2.6 m2.7 m2.4 m3.4 m3.6 m3.5 m5.7 m4.5 m4.9 m
USDY, 2018

Financial Leverage

2.7 x
Show all financial metrics

Regulus Therapeutics Operating Metrics

FY, 2016

Patents Issued

300
Show all operating metrics
Report incorrect company information

Regulus Therapeutics News and Updates

Report incorrect company information